“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

EGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at differ...

Full description

Bibliographic Details
Main Authors: Guoqing Zhang, Beibei Yan, Yanan Guo, Hang Yang, Jindong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
epidermal growth factor receptor
tyrosine kinase inhibitor
uncommon mutation
NSCLC
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.952939/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.952939/full

Similar Items